Analytical Data
-
Gene name
RLN1
- Application
-
Alternative Names
RLN1；Prorelaxin H1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04808
-
Expression Region
23-53aa
-
AA Sequence
VAAKWKDD VIKLCGRELV RAQIAICGMS TWS
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant RLN1 protein, a member of the relaxin family of peptides, plays a significant role in various physiological processes, including reproductive functions, cardiovascular regulation, and tissue remodeling. As a hormone primarily involved in pregnancy, RLN1 is known for its ability to relax uterine smooth muscle and facilitate childbirth. Recent research has highlighted its potential therapeutic applications beyond reproductive health, particularly in conditions such as heart failure, fibrosis, and other cardiovascular diseases, where its ability to promote vascular relaxation and improve blood flow can be beneficial. The production of recombinant RLN1 protein allows for detailed investigation of its biological activities and mechanisms of action. Utilizing advanced biotechnological methods, scientists can generate and purify this protein in adequate quantities, paving the way for in-depth studies on its pharmacokinetics, receptor interactions, and dose-response relationships. This research not only enhances our understanding of RLN1's role in human physiology but also suggests new avenues for clinical applications, including drug development targeting various pathologies. As RLN1 continues to capture attention in the fields of endocrinology and regenerative medicine, ongoing studies aim to elucidate its comprehensive functions and therapeutic potential, contributing to novel treatment strategies for a multitude of diseases.
